These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 25405650)

  • 21. Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer's disease.
    Teipel SJ; Sabri O; Grothe M; Barthel H; Prvulovic D; Buerger K; Bokde AL; Ewers M; Hoffmann W; Hampel H
    J Alzheimers Dis; 2013; 33 Suppl 1():S329-47. PubMed ID: 22735677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracellular amyloid-β accumulation in calcium-binding protein-deficient neurons leads to amyloid-β plaque formation in animal model of Alzheimer's disease.
    Moon M; Hong HS; Nam DW; Baik SH; Song H; Kook SY; Kim YS; Lee J; Mook-Jung I
    J Alzheimers Dis; 2012; 29(3):615-28. PubMed ID: 22269161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials.
    Siemers E; DeMattos RB; May PC; Dean RA
    Biomark Med; 2010 Feb; 4(1):81-9. PubMed ID: 20387304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased CSF Aβ during the very early phase of cerebral Aβ deposition in mouse models.
    Maia LF; Kaeser SA; Reichwald J; Lambert M; Obermüller U; Schelle J; Odenthal J; Martus P; Staufenbiel M; Jucker M
    EMBO Mol Med; 2015 Jul; 7(7):895-903. PubMed ID: 25978969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention.
    Vanitallie TB
    Metabolism; 2013 Jan; 62 Suppl 1():S30-3. PubMed ID: 23021038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain.
    Wu G; Miller RA; Connolly B; Marcus J; Renger J; Savage MJ
    Neurodegener Dis; 2014; 14(2):53-66. PubMed ID: 24158021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The pathophysiology of Alzheimer's disease with special reference to "amyloid cascade hypothesis"].
    Tamaoka A
    Rinsho Byori; 2013 Nov; 61(11):1060-9. PubMed ID: 24450113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer's disease and amyloid: culprit or coincidence?
    Skaper SD
    Int Rev Neurobiol; 2012; 102():277-316. PubMed ID: 22748834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
    McClean PL; Hölscher C
    Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer's disease.
    Kasai T; Kondo M; Ishii R; Tanaka A; Ataka S; Shimada H; Tomiyama T; Mori H; Taylor M; Allsop D; Nakagawa M; Mizuno T; Tokuda T
    PLoS One; 2017; 12(4):e0174630. PubMed ID: 28394917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.
    Hampel H; Shen Y; Walsh DM; Aisen P; Shaw LM; Zetterberg H; Trojanowski JQ; Blennow K
    Exp Neurol; 2010 Jun; 223(2):334-46. PubMed ID: 19815015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The amyloid hypothesis: let sleeping dogmas lie?
    Bishop GM; Robinson SR
    Neurobiol Aging; 2002; 23(6):1101-5. PubMed ID: 12470810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peripheral biomarkers of Alzheimer's disease.
    Khan TK; Alkon DL
    J Alzheimers Dis; 2015; 44(3):729-44. PubMed ID: 25374110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mass spectrometry is a multifaceted weapon to be used in the battle against Alzheimer's disease: Amyloid beta peptides and beyond.
    Grasso G
    Mass Spectrom Rev; 2019 Jan; 38(1):34-48. PubMed ID: 29905953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on biomarkers for amyloid pathology in Alzheimer's disease.
    Ashton NJ; Schöll M; Heurling K; Gkanatsiou E; Portelius E; Höglund K; Brinkmalm G; Hye A; Blennow K; Zetterberg H
    Biomark Med; 2018 Jul; 12(7):799-812. PubMed ID: 29902934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amyloidosis in Alzheimer's Disease: Pathogeny, Etiology, and Related Therapeutic Directions.
    Ma C; Hong F; Yang S
    Molecules; 2022 Feb; 27(4):. PubMed ID: 35209007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clarity on the blazing trail: clearing the way for amyloid-removing therapies for Alzheimer's disease.
    Lian Y; Jia YJ; Wong J; Zhou XF; Song W; Guo J; Masters CL; Wang YJ
    Mol Psychiatry; 2024 Feb; 29(2):297-305. PubMed ID: 38001337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathogenesis and Therapeutic Strategies in Alzheimer's Disease: From Brain to Periphery.
    Yu JT; Zhang C
    Neurotox Res; 2016 Feb; 29(2):197-200. PubMed ID: 26597964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nucleic acid aptamers as novel class of therapeutics to mitigate Alzheimer's disease pathology.
    Tannenberg RK; Shamaileh HA; Lauridsen LH; Kanwar JR; Dodd PR; Veedu RN
    Curr Alzheimer Res; 2013 May; 10(4):442-8. PubMed ID: 23270374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease.
    Oh ES; Troncoso JC; Fangmark Tucker SM
    Neuromolecular Med; 2008; 10(3):195-207. PubMed ID: 18543125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.